EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity

Yukihiro Wada, Masao Toyoda, Kazuo Kobayashi, Togo Aoyama, Akira Kanamori, Yasuo Takeuchi

Clinical and Experimental Nephrology · 2026-05 · 30 (5) · 747-756

DOI: 10.1007/s10157-026-02845-6 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Experimental Nephrology, online erschienen am 16.03.2026. Verfasst von Yukihiro Wada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-Ku, Sagamihara, Kanagawa, 224-0474, Japan. wada-y@kitasato-…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Glomerular Filtration Rate. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1Ra) have shown renoprotective effects in type 2 diabetes (T2D). Our previous findings suggested superior renal outcomes with SGLT2i compared to GLP-1Ra, particularly due to greater reductions in blood pressure (BP). However, whether this benefit extends to obese patients remains unclear. This study compared renal outcomes between SGLT2i and GLP-1Ra in obese Japanese patients with T2D. METHODS: This retrospective study included patients with T2D and body mass index ≥ 25 kg/m2 treated with either SGLT2i (n = 439) or GLP-1Ra (n = 174) for over one year. Patients receiving both drugs were excluded. The renal composite outcome was defined as an annual decline in estimated glomerular filtration rate (eGFR) > 30%, progression of albuminuria category, or both. Propensity score matching was applied to balance baseline characteristics. RESULTS: After matching (n = 89 per group), the incidence of renal events did not differ significantly between the two groups. The annual decline in eGFR tended to be smaller with SGLT2i than with GLP-1Ra (- 1.6 ± 3.5 vs. - 2.8 ± 5.8 mL/min/1.73 m2/year, p = 0.13). SGLT2i-treated patients also showed greater reductions in systolic BP and body weight (BW) (- 5.0 ± 19.7 vs. - 1.1 ± 18.0 mmHg, p = 0.19; - 3.3 ± 4.6 vs. - 1.9 ± 4.9 kg, p = 0.05, respectively). CONCLUSION: Among this population, the annual eGFR decline appeared numerically smaller with SGLT2i-tretament, without statistical significance. Greater BP and BW reductions were observed, though their impact on renal outcomes remains uncertain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsGlomerular Filtration RateObesityDiabetic NephropathiesKidneyHumansFemaleMaleRetrospective StudiesMiddle AgedJapanAgedAlbuminuriaTreatment OutcomeBlood PressureDisease ProgressionEast Asian People

Stichwörter der Autor:innen

GLP-1RaObesityRenal outcomeSGLT2i

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Nephrology, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-Ku, Sagamihara, Kanagawa, 224-0474, Japan. wada-y@kitasato-u.ac.jp.
  • Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Tokai University, Isehara, Japan.
  • Committee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.
  • Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Department of Health Management Center, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
  • Department of Nephrology, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-Ku, Sagamihara, Kanagawa, 224-0474, Japan.

Zitieren

APA

Wada, Y., Toyoda, M., Kobayashi, K., Aoyama, T., Kanamori, A., & Takeuchi, Y. (2026). Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity. Clinical and Experimental Nephrology, 30(5), 747-756. https://doi.org/10.1007/s10157-026-02845-6

Vancouver

Wada Y, Toyoda M, Kobayashi K, Aoyama T, Kanamori A, Takeuchi Y. Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity. Clinical and Experimental Nephrology. 2026;30(5):747-756. doi:10.1007/s10157-026-02845-6

BibTeX
@article{Wada2026,
  author = {Wada, Yukihiro and Toyoda, Masao and Kobayashi, Kazuo and Aoyama, Togo and Kanamori, Akira and Takeuchi, Yasuo},
  title = {Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity},
  journal = {Clinical and Experimental Nephrology},
  year = {2026},
  volume = {30},
  number = {5},
  pages = {747--756},
  doi = {10.1007/s10157-026-02845-6}
}
Kostenlos starten →